

Improving the CAR T-cell treatment journey and access to CAR T-cell therapy across Europe

E. Pennings^{1,2}, Y. Cabrerizo³, P. Lecot⁴, C. Sanges⁵, F. Thielen², U. Jaeger⁶, J. Delgado^{7,8}, A. Kremer⁹, M. Hudecek⁵, M. Luu⁵, N. Bolaños¹⁰, S. Clavreul¹¹, A. Kienesberger¹², S. Nier¹³, S. Sheth¹⁴, L. Gambotti⁴, C. Dreuillet⁴, H. Negre¹⁵, C. Uyl-de Groot², C. Girvalaki¹⁶, M.J. Kersten¹, On behalf of the T2Evolve (IMI) consortium

¹Amsterdam UMC, location University of Amsterdam, Hematology, Meibergdreef 9, Amsterdam, The Netherlands, Cancer Center Amsterdam, Amsterdam, The Netherlands and LYMMCARE; ²Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; ³European Hematology Association (EHA), The Hague, The Netherlands; ⁴Institut National du Cancer (French National Cancer Institute-INCa), Boulogne-Billancourt, France; ⁵Universitätsklinikum Würzburg, Würzburg, Germany; ⁶Medical University of Vienna, Vienna, Austria; ⁷Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; ⁸Hospital Clinic of Barcelona, Barcelona, Spain; ⁹Information Technology for Translational Medicine S.A., Esch-sur-Alzette, Luxembourg; ¹⁰Lymphoma Coalition Europe, Paris, France; ¹¹Myeloma Patients Europe, Brussels, Belgium; ¹²Childhood Cancer International Europe, Vienna, Austria; ¹³Acute Leukemia Advocates Network, Bern, Switzerland; ¹⁴BioSci Consulting, Maasmechelen, Belgium; ¹⁵Institut de Recherches Internationales Servier, Suresnes, France; ¹⁶European Cancer Patient Coalition, Brussels, Belgium

INTRODUCTION


- The European Consortium T2EVOLVE started in 2021, under the European Union's Innovative Medicines Initiative (IMI), with the key objective to accelerate the development of engineered T-cell therapies, such as Chimeric Antigen Receptor (CAR) T-cell therapy, to increase awareness and patient access to these therapies, and to provide guidance on sustainable integration of these treatments into the EU healthcare systems.
- To achieve this, involvement of patients, their caregivers and healthcare professionals is crucial. It is essential to understand their experiences, identify unmet needs and ensure their perspective is included in research.
- Here we present our research in which we engage all relevant stakeholders to evaluate how to improve the CAR T-cell treatment journey and patient access to CAR T-cell therapy for hematologic malignancies across Europe.

METHODS

- A structured approach combining a review of the current landscape, identification of gaps and needs and multi-stakeholder engagement is used.
- This approach ensures the research is focused on the most relevant topics at present.
- Mapping, listing, and categorization is used to provide an overview of the current landscape.
- Working groups, surveys and interviews are used to engage stakeholders, ensure their perspective is included and to identify and prioritize gaps and needs.

RESULTS

A working group consisting of patients, caregivers and patient organization representatives (WGPC) was established in 2021.



Between May 2021 and February 2023, 5 WGPC workshops were held to gather their views and to identify and prioritize gaps and needs.

CURRENT

European patient survey on CAR T-cell therapy


- A survey for **European adult patients (≥ 18 years) who received CAR T-cell therapy for a hematologic malignancy**, was developed by the T2EVOLVE and QUALITOP consortia in close collaboration with patient advocacy groups, patients and caregivers.
- This survey will help to understand patients' experiences with CAR T-cell therapy, evaluate the impact of this treatment on quality of life and identify unmet needs.
- With this information we aim to improve quality of life in patients receiving CAR T-cell therapy and their caregivers by optimizing support and improving the CAR T-cell treatment journey.
- The survey is available online in 7 languages:



Access it here: t2evolve.ty/patientsurvey

Patient hub – an online information repository for patients and caregivers

- Adequate communication to patients and their caregivers on CAR T-cell therapy is an essential part of the CAR T-cell treatment journey.
- Available educational material on CAR T-cell therapy for patients and caregivers in different European languages was identified and categorized.
- Together with the WGPC, information needs and gaps were identified, prioritized and 5 topics were selected for the development of new educational materials to address the identified information need.
- The patient hub is an online dynamic repository for information on CAR T-cell therapy and results of the T2EVOLVE consortium for patients and caregivers.



Access it here:



t2evolve.ty/patienthub


UPCOMING

Access roadmap

- How to improve access?
- Why a **pan-European effort**?
- Why is such therapy **meaningful/beneficial** for all EU patients & society?




- 1-on-1 interviews with various stakeholders involved in the field of CAR T-cell therapy.
- A survey for **European haematologists** was developed to collect information on access to commercially available CAR T-cell therapy for hematologic malignancies within Europe and to identify challenges and key learnings.
- A **patient-centered health technology assessment (HTA)** will be conducted and used to inform the access roadmap with respect to HTA and pricing



Explanatory videos

Selection and prioritization of 5 topics for which patients and caregivers from the WGPC identified a need for information:



HOW TO GET INVOLVED?

You can help T2EVOLVE with:

- Dissemination of materials** (e.g. survey, patient hub)
 - Input into future plans and new educational materials for patients and caregivers**
 - Recruitment of patients and caregivers for the WGPC**
- Join our **Stakeholder community!**
Check out www.t2evolve.com to join and present during our **Spotlight Sessions**.

Improving the CAR T-cell treatment journey and access to CAR T-cell therapy across Europe

ACKNOWLEDGEMENTS

We would like to thank all participants of the T2EVOLVE WGPC.

This project received funding from the innovative Medicines initiative 2 Joint Undertaking (JU) under grant agreement No 945393. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA. More information can be found at: <https://www.imi.europa.eu/>

